A Phase 4 interventional study of Atorvastatin and Pravastatin in Coronary Arteriosclerosis, sponsored by Pfizer. Completed at 36 sites in United States. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2006-12-04.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing atorvastatin in Coronary Artery Disease — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Coronary Artery Disease.
Among the 33 studies testing atorvastatin in Coronary Artery Disease, this one is the 3rd largest by enrollment, is the only one that started in 1999, is one of 19 in phase 4, and was the 4th registered.
4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 33 studies testing atorvastatin in Coronary Artery Disease is open now, in 1 country. Recruiting first, the newest first:
Fundación EPIC · Sites in Spain
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 120 across the 33 interventional studies. Of the 25 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 33 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing atorvastatin in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy. A substudy will examine the effect of these treatments on brachial artery vasoactivity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The primary efficacy parameter is the percent change in total plaque volume for all slices of anatomically comparable segments of the target coronary artery from baseline to month 18.
The primary efficacy parameter for brachial artery vasoactivity is the nominal change (month 3 - baseline) in the percent arterial diameter change.
The nominal change (month 18 - baseline) in total plaque volume as measured by the sum of plaque areas for all slices of anatomically comparable segments of the target coronary artery.
Changes in brachial artery vasoactivity will be correlated with changes in total cholesterol, LDL-C, triglyceride and apolipoprotein B levels following 3 months of treatment.
The record gives a start of Apr 1999 and a completion of Dec 2000. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atorvastatin · Pravastatin